Hyphens Pharma

Broker's Calls

CGSI ups Hyphens Pharma’s TP on ‘healthy pipeline’ of products ahead

CGS International analyst Tay Wee Kuang believes this will support patmi growth.

Broker's Calls

Analysts positive on Hyphens Pharma’s expansion into new markets

PhillipCapital and SAC Capital have kept “buy” on Hyphens at unchanged target prices of 35 cents and 38 cents respectively.

Broker's Calls

SAC Capital’s optimism intact on Hyphens Pharma following 1QFY2024 results

The analysts' positive outlook remains unchanged, expecting the announced initiatives to proceed as planned.
Hyphens Pharma secures Asean license for psoriasis treatment Wynzora Cream - THE EDGE SINGAPORE

Contracts

Hyphens Pharma secures Asean license for psoriasis treatment Wynzora Cream

Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and additional fees.

Results

Hyphens Pharma reports lower earnings of $8.57 million for FY2023 from heavier cost of sales

Hyphens Pharma's lower earnings of $8.57 million for FY2023 stem from heavier cost of sales, which increased by 9.2%.
Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma - THE EDGE SINGAPORE

Broker's Calls

Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma

Although the incremental net profit contribution is likely negligible near term, the deal presents cross-selling opportunities.

Company in the news

Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary

Hyphens Pharma sees the acquisition as a way to strengthen its Malaysian presence, first tranche worth $1.86 million.

Deals, joint ventures & alliances

Hyphens Pharma's DocMed partners Hoang Duc to digitalise pharmaceutical supply chain in Vietnam

Hyphens Pharma forms JV with Hoang Duc to digitalise Vietnam's pharmaceutical supply chain.
×